Healthier Communities Case Study – Advancing haemophilia care in Uzbekistan through partnership and humanitarian aid support with WFH CSL’s long-standing partnership with World Federation of Hemophilia highlights the impact of sustained collaboration in improving access to care for people with inherited bleeding disorders in underserved regions. A recent visit to Uzbekistan by CSL’s Global Policy and Advocacy Senior Director, Dr Sujan Sivasubramaniyam, in support of the WFH Humanitarian Aid Program, provided insights into both progress achieved and ongoing challenges in haemophilia care. Globally, an estimated 80–85% of people with haemophilia lack reliable access to effective treatment. In Uzbekistan, barriers such as limited diagnostic capabilities, low disease awareness and long travel distances to treatment centres contribute to delayed diagnosis and inadequate care. These challenges often result in preventable complications, including chronic pain, joint damage and reduced quality of life. Through the WFH Humanitarian Aid Program, supported by CSL for nearly two decades, patients in Uzbekistan are gaining access to essential clotting factor therapies. The program combines product donations with education, advocacy and healthcare capacity building, to create a more sustainable and reliable model of care. Engagement with local stakeholders, including clinicians, patient organisations and health authorities, underpins these efforts. Impact from CSL’s donations and financial support Dr Sivasubramaniyam’s visit demonstrated tangible improvements in patient outcomes and healthcare delivery, including the following: • Enhanced access to treatment: Increased availability of donated therapies is enabling more consistent treatment, including early prophylactic care for younger patients. • Improved quality of life: Early intervention is helping patients maintain mobility, reduces complications, and enables them to pursue education and career aspirations. • Strengthened healthcare systems: Facilities such as the Tashkent Haemophilia Centre are improving clinical care, supported by growing expertise and knowledge sharing. • Empowered patient advocacy: The Uzbek Society of Patients with Haemophilia is building capacity and influence, contributing to awareness and long-term system change. Despite progress, significant unmet needs remain, particularly in rural areas where access to diagnostics and treatment is limited. Many patients continue to experience delayed care and irreversible complications, underscoring the need for continued investment and collaboration. C SL’s partnership with WFH contributes to narrowing treatment gaps and drives measurable improvements in healthcare access and outcomes. In turn, this strengthens healthcare systems and advances more equitable care for people with haemophilia in emerging markets. Expanding access to influenza protection Science-backed, real-world evidence shows that vaccines protect people from serious illness and can save lives. Each year, across both hemispheres’ influenza seasons, CSL Seqirus’ influenza vaccines protect millions of people across the world from severe illness and ultimately save lives – helping to improve global health outcomes and alleviate the burden on healthcare systems. CSL Seqirus advances equitable access to vaccines through global partnerships. As a participant in the WHO’s Pandemic Influenza Preparedness (PIP) Framework, CSL Seqirus commits to supplying 10% of its real-time pandemic vaccine production to low- and middle-income countries, alongside financial contributions, supporting a more coordinated and inclusive global pandemic response. CSL Seqirus is also strengthening pandemic preparedness through strategic international agreements. This includes its recent long-term agreement signed in March 2026 with Pan American Health Organization (PAHO), working with Sinergium Biotech, which will enable access to millions of doses of pandemic influenza vaccine in Latin America and the Caribbean (LATAM), ensuring rapid availability during a WHO-declared pandemic. This builds on a long-term seasonal influenza collaboration, creating an integrated approach that strengthens both ongoing prevention and emergency readiness. Through technology transfer and co-investment in regional manufacturing and supply chains, CSL Seqirus is supporting local vaccine production, filling and distribution capacity in Latin America – improving supply reliability, scalability and long-term health system resilience. Additional recent pandemic preparedness agreements with governments, including Canada and Sweden, expand reserved vaccine supply and reinforce the Company’s ability to respond rapidly to emerging health threats, while strengthening global readiness infrastructure. Beyond influenza, CSL Seqirus continues to improve patient access to medicines. The recent launch of a novel needle-free adrenaline (epinephrine) nasal spray, NEFFY®, and transition of RYALTRIS® to over-the-counter availability in Australia, demonstrates its commitment to making effective treatments more accessible, enabling more timely and convenient care for patients. 27 year old Javlon, who lives with severe hemophilia B in Uzbekistan, was able to get much needed surgery with CSL’s product donation. 28 Healthier World
RkJQdWJsaXNoZXIy MjE2NDg3